Edition:
India

Vascular Biogenics Ltd (VBLT.OQ)

VBLT.OQ on NASDAQ Stock Exchange Global Market

7.70USD
17 Jan 2018
Change (% chg)

$0.15 (+1.99%)
Prev Close
$7.55
Open
$7.55
Day's High
$7.70
Day's Low
$7.55
Volume
23,442
Avg. Vol
60,038
52-wk High
$9.05
52-wk Low
$3.95

Chart for

About

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company's program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly... (more)

Overall

Beta: --
Market Cap(Mil.): $157.27
Shares Outstanding(Mil.): 27.12
Dividend: --
Yield (%): --

Financials

BRIEF-Vascular Biogenics Says Top-Line Data From Globe Phase 3 Pivotal Trial Of VB-111 Expected In Q1 Of 2018

* VASCULAR BIOGENICS - TOP-LINE DATA FROM GLOBE PHASE 3 PIVOTAL TRIAL OF VB-111 EXPECTED IN Q1 OF 2018 Source text for Eikon: Further company coverage:

27 Dec 2017

BRIEF-Vascular Biogenics Files For Mixed Shelf Of Up To $150 Mln - SEC Filing

* VASCULAR BIOGENICS LTD FILES FOR MIXED SHELF OF UP TO $150 MILLION - SEC FILING Source text: (http://bit.ly/2CY4IXN) Further company coverage:

19 Dec 2017

BRIEF-VBL therapeutics prices 2.5 mln ordinary share offering

* VBL Therapeutics prices 2.5 million ordinary share offering

17 Nov 2017

BRIEF-VBL Therapeutics announces proposed public offering of 2.5 mln shares of ordinary shares

* VBL Therapeutics announces proposed public offering of 2.5 million shares of ordinary shares Source text for Eikon: Further company coverage:

17 Nov 2017

BRIEF-VBL therapeutics Q3 loss per share $0.24

* VBL Therapeutics announces third quarter 2017 financial results

14 Nov 2017

BRIEF-VBL Therapeutics and Nanocarrier signs agreement for VB-111 in Japan

* VBL Therapeutics and Nanocarrier Co Ltd sign exclusive agreement for VB-111 in Japan

06 Nov 2017

BRIEF-VBL THERAPEUTICS OPENS NEW GENE THERAPY MANUFACTURING PLANT, HEADQUARTERS

* VBL THERAPEUTICS CELEBRATES OPENING OF ITS NEW GENE THERAPY MANUFACTURING PLANT AND COMPANY HEADQUARTERS

23 Oct 2017

BRIEF-VBL Therapeutics says VB-111 given orphan drug designation in Europe

* VBL Therapeutics announces orphan drug designation for VB-111 in Europe

20 Oct 2017

BRIEF-Vascular Biogenics reports Q2 loss per share $0.18

* Vbl therapeutics announces second quarter 2017 financial results

14 Aug 2017

Earnings vs. Estimates